Combined hepatocellular carcinoma and cholangiocarcinoma | UniteRare Disease Library

Treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or …

Treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements

View Details →

Truseltiq

infigratinib· QED Therapeutics, Inc.Orphan Drug

Treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected…

Treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. (Indication withdrawn 5/16/2024)

View Details →

Clinical Trials

20 recruitingView all trials with filters →

Phase 34 trials

Improved Recovery by Iron Following Surgery With Blood Loss, the IRIS-trial

Phase 3

Actively Recruiting

· Sites: Uppsala, Sverige · Age: 18–99 yrs

Patient Controlled Epidural Analgesia Versus Intravenous Patient Controlled Analgesia for Post-Operative Pain Control in Patients Undergoing Elective Liver Resection

Phase 3

Active

PI: Vittoria Arslan-Carlon, MD (Memorial Sloan Kettering Cancer Center) · Sites: Basking Ridge, New Jersey; Commack, New York +1 more · Age: 18–99 yrs

Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC

Phase 3

Actively Recruiting

PI: Jinbo Yue, Doctor (Shandong Cancer Hospital and Institute) · Sites: Jinan, Shandong · Age: 18–75 yrs

DEB-TACE vs cTACE in HCC After TIPS

Phase 3

Actively Recruiting

· Sites: Guangzhou, Guangdong · Age: 18–75 yrs

Phase 41 trial

National Liver Cancer Screening Trial

Phase 4

Actively Recruiting

PI: Amit Singal, MD, MS (University of Texas Southwestern Medical Center) · Sites: Los Angeles, California; Redwood City, California +16 more · Age: 18–85 yrs

Phase 23 trials

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

Phase 2

Actively Recruiting

· Sites: Edmonton, Alberta · Age: 18–99 yrs

Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion

Phase 2

Actively Recruiting

PI: Jeong Il Yu, MD, PhD (Samsung Medical Center) · Sites: Seoul · Age: 20–99 yrs

A Phase II Single-Arm Clinical Study to Evaluate the Efficacy and Safety of Carbon Ion Radiotherapy With Atezolizumab and Bevacizumab Combination Therapy in Patients With Advanced Hepatocellular Carcinoma

Phase 2

Actively Recruiting

· Sites: Seoul · Age: 20–99 yrs

Phase 11 trial

Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)

Phase 1

Active

PI: David Steffin, M.D. (Baylor College of Medicine) · Sites: Houston, Texas · Age: 1–21 yrs

N/A5 trials

TARGETed Therapy Drug MONITOring in DIGestive Oncology

N/A

Actively Recruiting

PI: David MALKA, Dr (Gustave ROUSSY - VILLEJUIF) · Sites: Amiens; Auxerre +27 more · Age: 18–99 yrs

TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors

N/A

Actively Recruiting

· Sites: Tianjin · Age: 18–75 yrs

DEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCC

N/A

Actively Recruiting

PI: Gao-Jun Teng (Zhongda Hospital) · Sites: Beijing, Beijing Municipality; Nanjing, Jiangsu · Age: 18–80 yrs

Biannual Screening for HCC Offered to Patients With Cirrhosis. Introducing Surveillance for Hepatocellular Carcinoma (HCC) in the Central Denmark Region Using Ultrasound and Alpha-Fetoprotein to Reduce HCC-Related Mortality in Patients With Compensated Non-Viral Cirrhosis

N/A

Actively Recruiting

· Sites: Aarhus, Central Jutland; Herning, Central Jutland +4 more · Age: 40–79 yrs

Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions

N/A

Active

PI: Janio Szklaruk, MD, PHD (M.D. Anderson Cancer Center) · Sites: Houston, Texas · Age: 18–99 yrs

Other5 trials

Validation of SMS Protocol for HCC Screening in High-risk Patients

Enrolling by Invitation

PI: Prof. Dr. de Man (Erasmus Medical Center) · Sites: Amsterdam, North Holland; Enschede, Overijssel +4 more · Age: 18–99 yrs

Radiotherapy Delays Second-line Drug Therapy for Oligo Progressive Primary Liver Cancer

Actively Recruiting

PI: jibo yue, dorctor (Shandong Cancer Hospital and Institute) · Sites: Jinan, Shandong · Age: 18–75 yrs

An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer

Actively Recruiting

PI: Ajay Goel, PhD (City of Hope Medical Center) · Sites: Duarte, California; Fukuoka +3 more · Age: 18–99 yrs

naVIGation Invitations Liver surveillANce upTake

Active

· Sites: London · Age: 18–99 yrs

Active Choice Clinical Decision Support (CDS): Hepatocellular Carcinoma (HCC) Screening in Patients With Cirrhosis

Enrolling by Invitation

PI: Saul Blecker (NYU Langone Health) · Sites: New York, New York · Age: 18–99 yrs

Specialists

20 foundView all specialists →

WM

William R. Jarnagin, MD

NEW YORK, NY

Specialist

PI on 1 active trial

Overview

FDA & Trial Timeline

Treatments

Clinical Trials

Specialists

Treatment Centers

Financial Resources

Travel Grants

Community

Latest news about Combined hepatocellular carcinoma and cholangiocarcinoma

Caregiver Resources

Common questions about Combined hepatocellular carcinoma and cholangiocarcinoma